Phibro Animal Health (NASDAQ:PAHC - Get Free Report) had its price target raised by Morgan Stanley from $21.00 to $26.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an "equal weight" rating on the stock. Morgan Stanley's target price indicates a potential upside of 4.73% from the company's previous close.
PAHC has been the subject of a number of other research reports. Wall Street Zen raised shares of Phibro Animal Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price objective on the stock in a report on Monday, June 16th. Finally, BNP Paribas raised Phibro Animal Health to a "hold" rating in a research note on Monday, June 16th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $21.80.
Read Our Latest Analysis on PAHC
Phibro Animal Health Price Performance
Shares of NASDAQ PAHC traded up $0.06 during mid-day trading on Wednesday, reaching $24.83. 117,689 shares of the company were exchanged, compared to its average volume of 207,146. The stock has a market capitalization of $1.01 billion, a PE ratio of 31.83, a PEG ratio of 0.46 and a beta of 0.74. The company has a quick ratio of 1.23, a current ratio of 2.91 and a debt-to-equity ratio of 2.67. Phibro Animal Health has a 52 week low of $16.16 and a 52 week high of $26.55. The company's 50 day moving average price is $22.14 and its 200 day moving average price is $21.94.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.52 by $0.11. The firm had revenue of $347.80 million during the quarter, compared to analysts' expectations of $352.41 million. Phibro Animal Health had a return on equity of 30.51% and a net margin of 2.68%. Sell-side analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Phibro Animal Health
Large investors have recently made changes to their positions in the business. Sterling Capital Management LLC lifted its stake in Phibro Animal Health by 2.4% in the fourth quarter. Sterling Capital Management LLC now owns 18,762 shares of the company's stock worth $394,000 after acquiring an additional 448 shares during the period. Rhumbline Advisers raised its holdings in Phibro Animal Health by 0.6% in the 4th quarter. Rhumbline Advisers now owns 76,582 shares of the company's stock worth $1,608,000 after purchasing an additional 484 shares in the last quarter. Los Angeles Capital Management LLC lifted its position in shares of Phibro Animal Health by 2.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 24,042 shares of the company's stock worth $505,000 after purchasing an additional 503 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Phibro Animal Health by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company's stock valued at $260,000 after purchasing an additional 546 shares in the last quarter. Finally, Algert Global LLC increased its position in shares of Phibro Animal Health by 1.4% during the first quarter. Algert Global LLC now owns 97,612 shares of the company's stock valued at $2,085,000 after buying an additional 1,340 shares during the period. 99.34% of the stock is currently owned by institutional investors.
About Phibro Animal Health
(
Get Free Report)
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Phibro Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.
While Phibro Animal Health currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
